PTGS2 and breast neoplasm: As PIK3CA mutations are reported in 10-40% of BCs [21] we hypothesized that mutated-PIK3CA breast tumor expressing COX-2 could benefit from treatment with a COX-2 inhibitor such as celecoxib.